The classic psychedelics are grouped by a shared mechanism — agonism at the serotonin 5-HT2A receptor — not by chemistry, which is why a tryptamine (psilocybin, DMT), an ergoline (LSD), and a phenethylamine (mescaline) sit in the same category. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 They differ sharply on everything else: potency scale, duration, [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9 and especially how much microdosing research exists. This page lays those differences side by side as a description, never a ranking. The most important column is the last: research is concentrated in psilocybin and LSD, while DMT and mescaline have essentially no controlled microdosing evidence. [3] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 Pharmacological similarity is not interchangeability — sharing a receptor does not make these compounds equivalent for microdosing.
This is an education-only research comparison, not sourcing, dosing, medical, or legal advice. It describes how the classic psychedelics differ on objective features. It does not rank them, recommend one over another, or advise use, dosing, or sourcing, and it issues no safe-or-unsafe verdict. For personal decisions, consult a qualified clinician.
Comparison is not ranking. The purpose of this page is to show where substances differ, not to identify which is preferable. “Better studied” describes the quantity of research, not a recommendation; nothing here implies one compound is best, safest, or preferred. This is a research-literacy map, not a selection guide.
One mechanism, four chemistries
What unites the classic psychedelics is that they are 5-HT2A receptor agonists; that single pharmacological fact is the definition. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 What divides them is almost everything else. Psilocybin and DMT are tryptamines, structurally close to serotonin. LSD is an ergoline. Mescaline is a phenethylamine — the same broad family as MDMA and the amphetamines, which is a useful reminder that chemical family does not predict subjective category. [4] Peer-reviewed Dark Classics in Chemical Neuroscience: Mescaline doi:10.1021/acschemneuro.8b00215 Reading “classic psychedelic” as a chemical statement is a common error; it is a mechanism label.
The features that actually differ
Beyond the shared target, the compounds diverge on potency, onset, duration, and route. LSD is active in micrograms with a long duration confirmed in controlled pharmacokinetics. [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9 DMT is so rapidly broken down by monoamine oxidase that it is inactive orally unless combined with an enzyme inhibitor, which is the pharmacological basis of ayahuasca; on its own it is short and intense. [5] Peer-reviewed Dark Classics in Chemical Neuroscience: N,N-Dimethyltryptamine (DMT) doi:10.1021/acschemneuro.8b00101 Mescaline is comparatively low in potency, requiring far larger amounts, with a long duration. [4] Peer-reviewed Dark Classics in Chemical Neuroscience: Mescaline doi:10.1021/acschemneuro.8b00215 These are descriptive facts about the molecules, not reasons to prefer one.
| Feature | Psilocybin | LSD | DMT (alone) | Mescaline |
|---|---|---|---|---|
| Chemical family | Tryptamine | Ergoline | Tryptamine | Phenethylamine |
| Main target | 5-HT2A agonist | 5-HT2A agonist | 5-HT2A agonist | 5-HT2A agonist |
| Active quantity | Milligrams | Micrograms | Milligrams | Hundreds of mg |
| Oral activity | Yes (prodrug) | Yes | No (needs MAOI) | Yes |
| Perceptual duration | ~4–6 h | ~8–12 h | Minutes (smoked) | ~10–12 h |
The column that matters most: evidence
A comparison of mechanisms can give a false impression that all four are equally studied. They are not. A systematic review of low-dose psychedelic research found the entire microdosing field thin and self-report-dominated — and within it, the work is overwhelmingly psilocybin and LSD. [3] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 DMT and mescaline are rarely microdosed and have essentially no controlled low-dose human evidence; what is known about them comes from full doses and from chemistry and pharmacology reviews. [5] Peer-reviewed Dark Classics in Chemical Neuroscience: N,N-Dimethyltryptamine (DMT) doi:10.1021/acschemneuro.8b00101 [4] Peer-reviewed Dark Classics in Chemical Neuroscience: Mescaline doi:10.1021/acschemneuro.8b00215
| If you compare… | You learn… |
|---|---|
| Receptor target | They are pharmacologically related (all 5-HT2A agonists) |
| Potency and duration | They are practically very different molecules |
| Microdosing evidence | Only psilocybin and LSD are studied at all; the rest are not |
| Subjective category | Chemical family does not predict it (mescaline ≠ MDMA in effect) |
Why “similar” does not mean “swappable”
The temptation, once you know these compounds share a receptor, is to assume findings transfer between them — that because psilocybin microdosing has been surveyed, mescaline microdosing is similarly supported. It is not. Differences in potency, duration, metabolism, and the sheer absence of low-dose evidence for most of them mean pharmacological similarity is not interchangeability. A claim built on psilocybin or LSD data does not automatically extend to DMT or mescaline. For the underlying mechanism these compounds share, see the 5-HT2A mechanism and the pharmacology overview; for the compounds rarely microdosed, other classic psychedelics.
- Mechanism category
- ”Classic psychedelic” means 5-HT2A agonist; it is not a chemical class. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
- Different molecules
- Potency, duration, and route differ sharply across the four. [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9
- Concentrated evidence
- Microdosing research is essentially psilocybin and LSD only. [3] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
- Similar ≠ swappable
- A shared receptor does not make findings transfer between compounds.
Frequently asked questions
What makes a psychedelic a 'classic' psychedelic?
The defining feature is mechanism, not chemistry: classic psychedelics are agonists at the serotonin 5-HT2A receptor. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 That single shared target is why psilocybin, LSD, DMT, and mescaline are grouped together despite belonging to different chemical families — tryptamines, an ergoline, and a phenethylamine respectively. Substances such as ketamine and MDMA are often called psychedelics in everyday speech but do not fit this pharmacological definition, which is why they are treated separately in this cluster.
Is this comparison telling me which one is best?
No. It is a description of how the classic psychedelics differ on objective features — chemical family, main receptor target, typical duration, and the size of their research base — not a ranking of effectiveness, safety, or suitability. Phrases like “most studied” describe the quantity of literature, not a recommendation. [3] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 Which substance, if any, is appropriate for a person is a dosing, medical, and legal question this cluster does not answer; it routes those elsewhere by design.
If they share a receptor, are they interchangeable?
No. A shared 5-HT2A target does not make the classic psychedelics equivalent. They differ in potency scale, duration, receptor-binding breadth, metabolism, and — crucially — in how much microdosing research exists for each. [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9 Pharmacological similarity is not interchangeability: evidence about psilocybin microdosing does not automatically apply to mescaline, and a comparison of mechanisms is not a statement that swapping one for another preserves any reported effect.
Why is the microdosing evidence so uneven across them?
Because research follows availability, duration, and prior use. Psilocybin and LSD are the substances people actually microdose and the ones surveys and the few trials examine; DMT and mescaline are rarely microdosed and have essentially no controlled low-dose evidence. [5] Peer-reviewed Dark Classics in Chemical Neuroscience: N,N-Dimethyltryptamine (DMT) doi:10.1021/acschemneuro.8b00101 [4] Peer-reviewed Dark Classics in Chemical Neuroscience: Mescaline doi:10.1021/acschemneuro.8b00215 So the comparison’s most honest column is the last one: the evidence base is concentrated in two compounds, and for the others the pharmacology is described far better than any microdosing effect.
Which classic psychedelic is best for microdosing?
This cluster does not rank substances or recommend use. It explains how the evidence differs across compounds, and “better studied” does not mean recommended, safer, or more effective. [3] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 The most that can be said is that psilocybin and LSD are more directly represented in microdosing research than DMT or mescaline — which is a statement about where evidence exists, not about what anyone should take. Selection, dosing, and suitability are outside this cluster’s scope by design.